We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MTD:NYSEMettler-Toledo International, Inc. Analysis

Data as of 2026-03-10 - not real-time

$1,236.30

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Mettler‑Toledo delivered a strong Q4 finish, posting EPS of $13.36 versus the consensus $12.76 and an 8% revenue increase to $1.1 billion, underscoring its resilient demand across laboratory and industrial segments. Operating margins remain robust at 30.7% and free cash flow exceeds $687 million, supporting continued investment in automation and AI‑driven solutions. The company’s balance sheet shows ample liquidity with $66.9 million cash, though debt sits near $2.27 billion, resulting in a neutral debt‑to‑equity profile. Technical indicators signal mixed short‑term sentiment: the 14‑day RSI is low at 29, suggesting oversold conditions, while the MACD remains bearish and the price trades below its 20‑day (1339) and 50‑day (1392) SMAs. Support at $1,193 holds the current price of $1,236, but the 30‑day volatility of 24% and a beta of 1.44 point to heightened price swings. Valuation appears stretched, with a market price of $1,236 versus a DCF‑derived fair value of roughly $550 and a forward P/E of 24 against the industry average of 25.3. The market sentiment index reads “Extreme Greed” at 80.6, hinting at potential overenthusiasm. Overall, the stock combines solid earnings momentum with a premium valuation and elevated risk factors.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • Oversold RSI indicating near‑term price rebound potential
  • Recent earnings beat and accelerating revenue growth
  • Increasing trading volume supporting momentum

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Strong operating margins and free cash flow generation
  • Valuation premium relative to DCF and peers
  • Broad product diversification across life‑science and industrial markets

Long Term

> 3 years
Cautious
Model confidence: 5/10

Key Factors

  • Significant overvaluation risk if market corrects toward DCF
  • High regulatory exposure in the diagnostics segment
  • Absence of dividend reduces total return appeal

Key Metrics & Analysis

Financial Health

Revenue Growth8.10%
Profit Margin21.59%
P/E Ratio29.4
ROA20.35%
P/B Ratio-1064.9
Op. Cash Flow$955.8M
Free Cash Flow$687.1M
Industry P/E25.4

Technical Analysis

TrendNeutral
RSI29.4
Support$1,192.85
Resistance$1,422.36
MA 20$1,338.78
MA 50$1,392.00
MA 200$1,319.65
MACDBearish
VolumeIncreasing
Fear & Greed Index80.57

Valuation

Fair Value$549.71
Target Price$1,501.38
Upside/Downside21.44%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.19
Volatility23.92%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.